Shire Reports Analysis Examining Emotional Lability In Children With ADHD Taking Vyvanse | Psydir News

Links shared publicly online about this topic.

1,603
total visits

Shire Reports Analysis Examining Emotional Lability In Children With ADHD Taking Vyvanse | Psydir News

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Sc...

View full resource at news.psydir.com

Tags: ADHD Medication, Emotional Health, Disease and Condition, Phase 3 Clinical Trial, Parenting, Children's Health, Vyvanse, Shire